Biocept (BIOCQ) 10-Q14 May 142014 Q1 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2014	8-May-14
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'BIOC	'
Entity Registrant Name	'BIOCEPT INC	'
Entity Central Index Key	'0001044378	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	4,449,594

Condensed_Balance_Sheets_Unaud

Condensed Balance Sheets (Unaudited) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$10,417,277	$69,178
Accounts receivable	26,000	9,200
Inventories, net	96,904	92,823
Prepaid expenses and other current assets	447,596	799,131
Total current assets	10,987,777	970,332
Fixed assets, net	301,231	358,887
Other non-current assets	500	500
Total assets	11,289,508	1,329,719
Current liabilities:	'	'
Accounts payable	952,096	1,540,618
Accrued liabilities	480,559	2,242,058
Line of credit	0	1,981,000
Notes payable	0	5,200,599
Warrant liability	6,538	2,140,532
Supplier financings	20,457	218,925
Total current liabilities	1,459,650	13,323,732
Deferred rent	473,080	462,001
Total liabilities	1,932,730	13,785,733
Commitments and contingencies (see Note 8)	'	'
Shareholders' equity/(deficit):	'	'
Series A convertible preferred stock, $0.0001 par value, 100,000,000 authorized; 69,421,047 issued and outstanding at December 31, 2013; 5,000,000 shares authorized; no shares issued and outstanding at March 31, 2014; liquidation preference of $41,652,628 at December 31, 2013 (see Note 2).	0	6,942
Common stock, $0.0001 par value, 53,000,000 authorized; 185,550 issued and outstanding at December 31, 2013; 40,000,000 authorized; 4,449,594 issued and outstanding at March 31, 2014 (see Note 2).	445	19
Additional paid-in capital	136,905,180	109,958,001
Accumulated deficit	-127,548,847	-122,420,976
Total shareholders' equity/(deficit)	9,356,778	-12,456,014
Total liabilities and shareholders' equity/(deficit)	$11,289,508	$1,329,719

Condensed_Balance_Sheets_Unaud1

Condensed Balance Sheets (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Series A convertible preferred stock, par value	$0.00	$0.00
Series A convertible preferred stock, shares authorized	5,000,000	100,000,000
Series A convertible preferred stock, shares outstanding	0	69,421,047
Series A convertible preferred stock, shares issued	0	69,421,047
Series A convertible preferred stock, liquidation preference	'	$41,652,628
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	40,000,000	53,000,000
Common stock, shares issued	4,449,594	185,550
Common stock, shares outstanding	4,449,594	185,550

Condensed_Statements_of_Operat

Condensed Statements of Operations and Comprehensive Loss (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]	'	'
Revenues	$28,275	$35,154
Cost of revenues	658,315	547,251
Gross profit/(loss)	-630,040	-512,097
Operating expenses	'	'
Research and development expenses	1,008,929	710,206
General and administrative expenses	1,876,912	451,157
Sales and marketing expenses	11,142	96,404
Loss from operations	-3,527,023	-1,769,864
Other income/(expense)	'	'
Interest expense, net	-1,394,444	-467,564
Change in fair value of warrant liability	-206,404	317,993
Other income/(expense)	0	-5,739
Total other income/(expense)	-1,600,848	-155,310
Loss before income taxes	-5,127,871	-1,925,174
Income tax expense	0	-800
Net loss & comprehensive loss	($5,127,871)	($1,925,974)
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:	'	'
Basic	2,617,275	180,540
Diluted	2,617,275	180,540
Net loss per common share:	'	'
Basic	($1.96)	($10.67)
Diluted	($1.96)	($10.67)

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
Condensed Statements of Cash Flows (Unaudited) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Cash Flows From Operating Activities	'	'
Net loss	($5,127,871)	($1,925,974)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	57,656	69,452
Inventory reserve	-601	-29,856
Stock-based compensation	894,940	10,510
Non-cash interest expense related to convertible debt and other financing activities	1,382,777	465,799
Change in fair value of warrant liabilities	206,404	-317,993
Increase/(decrease) in cash resulting from changes in:	'	'
Accounts receivable	-16,800	-12,211
Inventory	-3,480	1,274
Prepaid expenses and other current assets	-393,902	125,156
Accounts payable	-830,735	-151,547
Accrued liabilities	-1,272,654	-16,271
Deferred rent	11,079	-2,850
Net cash used in operating activities	-5,093,187	-1,784,511
Cash Flows From Investing Activities	'	'
Purchases of fixed assets	0	0
Net cash used in investing activities	0	0
Cash Flows From Financing Activities	'	'
Proceeds from exercise of stock options	0	65
Net proceeds from issuance of common stock	17,390,240	0
Payments on supplier and other third party financings	-142,954	-22,846
Payments on line of credit	-2,346,000	0
Proceeds from borrowings on line of credit	365,000	0
Proceeds from issuance of convertible notes and warrants	175,000	1,640,000
Net cash provided by financing activities	15,441,286	1,617,219
Net increase/(decrease) in Cash and Cash Equivalents	10,348,099	-167,292
Cash and Cash Equivalents at Beginning of Period	69,178	185,256
Cash and Cash Equivalents at End of Period	10,417,277	17,964
Cash paid during the period for:	'	'
Interest	152,507	1,765
Taxes	$0	$800

Condensed_Statements_of_Cash_F1

Condensed Statements of Cash Flows (Unaudited) (Parenthetical) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Common stock, shares issued for restricted stock units	'	21,846
Common stock, par value	$0.00	$0.00
Cancellation of insurance premiums amount	$44,559	'
Cancellation of insurance premiums partial amount received	10,955	'
Fair value of common stock warrants issued in conjunction with guarantees on additional borrowings	135,222	'
Series A Preferred Stock, shares converted to common stock	69,421,047	'
Common stock, shares issued upon conversion of Series A Preferred Stock	1,652,851	'
Purchase of common stock by underwriters to cover overallotments, number of shares	285,000	'
Purchase of common stock by underwriters to cover overallotments, per share	$9.30	'
Purchase of common stock by underwriters to cover overallotments, grant date fair value	202,143	'
Overallotment issued to underwriter to purchase common stock, period	'45 days	'
Warrants to purchase common stock, period	'5 years	'
Issuance of warrants to purchase shares of common stock, grant date fair value	544,116	'
Underwriter IPO costs	279,760	'
Non-cash discount	1,330,000	'
Derivative warrant liabilities	2,475,620	'
Warrants reclassified to additional paid-in capital	387,152	'
Exercise price of warrants	10	'
Additional costs incurred prior to, and associated with IPO, beginning of period	932,136	'
Corresponding liabilities, end of period	242,213	'
Aegis Capital Corp. [Member]	'	'
Issuance of warrants to purchase shares of common stock	95,000	'
Exercise price of warrants	12.5	'
2008 Convertible Note [Member]	'	'
Convertible Note, principal amount	1,400,000	'
Convertible Note, accrued interest	233,982	'
Conversion price of notes	$10	'
Convertible Note converted into common stock	163,399	'
2013 Convertible Bridge Notes [Member]	'	'
Convertible Note, principal amount	5,165,000	'
Convertible Note, accrued interest	$313,017	'
Conversion price of notes	$10	'
Convertible Note converted into common stock	547,794	'

Basis_of_Presentation

Basis of Presentation	3 Months Ended
Basis of Presentation	Mar. 31, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	1. Basis of Presentation
	Basis of Presentation
	The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America.
	The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission (“SEC”) instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles (“GAAP”) to be included in a full set of financial statements. The unaudited condensed balance sheet at December 31, 2013 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2013, filed with the SEC with our Annual Report on Form 10-K on March 28, 2014 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.
	The Company and Business Activities
	Biocept, Inc. (“the Company”) was founded in California in May 1997 and is a commercial-stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) tests utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor.
	The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures CEE microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic tests in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The tests the Company offers are classified as laboratory developed tests (LDTs), under the CLIA regulations.
	In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.
	Recent Accounting Pronouncements
	In July 2013, the FASB issued authoritative guidance which requires netting unrecognized tax benefits against deferred tax assets for a loss or other carryforward that would apply in settlement of uncertain tax positions. This guidance is effective for annual reporting periods beginning after December 15, 2013, and was effective for the Company’s fiscal year beginning January 1, 2014. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures.

Initial_Public_Offering

Initial Public Offering	3 Months Ended
Initial Public Offering	Mar. 31, 2014
Text Block [Abstract]	'
Initial Public Offering	'
	2. Initial Public Offering
	Pursuant to an underwriting agreement dated February 4, 2014 between the Company and Aegis Capital Corp. (“Aegis”), as representative of the several underwriters named therein, an IPO of 1,900,000 shares of common stock at $10.00 per share was effected on February 5, 2014. The closing of the sale of these shares to the underwriters occurred on February 10, 2014. The Company received, after deducting underwriting discounts and additional costs paid to the underwriters, approximately $17,390,000 of net cash proceeds from the sale of these 1,900,000 shares. The total increase in capital as a result of the sale of these shares was approximately $16,458,000 after deducting $932,136 of additional non-underwriter costs incurred that are netted against these proceeds under applicable accounting guidance. Additionally, the underwriters were granted a 45 day option from the closing date of the IPO to purchase up to 285,000 shares of common stock at $9.30 per share to cover overallotments with a grant date fair value of $202,143 (see Note 4), which was not exercised. In addition, designees of Aegis were issued warrants to buy (in the aggregate) up to 95,000 shares of common stock at $12.50 per share with a term of five years and a grant date fair value of $544,116 (see Note 4).
	On February 4, 2014, as contemplated by the registration statement covering the IPO, 69,421,047 shares of outstanding Series A Preferred Stock were converted into 1,652,851 shares of common stock and the Company’s certificate of incorporation was amended to provide for an authorized capitalization of 40,000,000 shares of common stock and 5,000,000 shares of preferred stock.
	In connection with the closing of the Company’s IPO on February 10, 2014, (i) the $1,400,000 principal amount and $233,982 of accrued interest related to the 2008 Convertible Note were converted at $10.00 per share into a total of 163,399 shares of common stock, (ii) the $5,165,000 principal amount and $313,017 of accrued interest related to the 2013 Convertible Bridge Notes were converted at $10.00 per share into a total of 547,794 shares of common stock, (iii) the exercise price of the warrants associated with the 2013 Bridge Notes was fixed at $10.00 per share for an aggregate 258,249 shares of common stock, (iv) the exercise price of the warrants associated with the $2,578,104 of collateral provided to secure the Company’s Line of Credit was fixed at $10.00 per share for an aggregate 128,903 shares of common stock, (v) 73,151 shares of common stock vested as settlement of certain restricted stock units (which were previously expressed in shares of preferred stock) and became issuable subsequent to the expiration of the 180 day lock-up period, (vi) the Company’s Executive Chairman ceased to be an employee and continues to serve as non-executive Chairman, (vii) the number of shares of common stock covered by the 2013 Equity Incentive Plan increased by 800,000, (viii) all but 1,587 of the preferred warrants previously outstanding were canceled due to early termination clauses associated with the IPO, (ix) derivative warrant liabilities of $2,475,620 associated with the aggregate of 387,152 common stock warrants related to the Company’s 2013 Convertible Bridge Notes and Line of Credit were reclassified to additional paid-in capital when their underlying exercise price was fixed, (x) unamortized discounts of $996,024 related to the warrants associated with the 2013 Convertible Bridge Notes and Line of Credit were reclassified to interest expense, and (xi) offering costs associated with the IPO of $932,136 were reclassified from prepaid expenses and other current assets to additional paid-in capital, while additional underwriter IPO costs and discounts of $279,760 and $1,330,000, respectively, were netted against the proceeds from the IPO and are reflected as an offset to additional paid-in capital.
	Subsequent to December 31, 2013, the maximum amount of the Company’s Line of Credit was increased to approximately $2.6 million and common stock warrants were issued to four shareholders in conjunction with their guarantees on the Company’s additional borrowings under the line of credit. On February 10, 2014, the current outstanding balance under the line of credit of $2,346,000 plus accrued interest of $27,043 was paid in full using the net proceeds from the IPO.
	On February 13, 2014, the Compensation Committee of the Company’s Board of Directors approved the payment of an aggregate $1,009,552 in deferred salary obligations, including contractual interest, to current and former named executive officers pursuant to previously existing agreements, which was fully disbursed by April 2014 using the net proceeds from the IPO. An additional $344,883 in deferred salary obligations and interest thereon was paid to former employees other than named executive officers. Also on February 13, 2014, in connection with the closing of the IPO and pursuant to a Board resolution for a director compensation policy adopted in 2013, the Company’s Board of Directors approved annual cash retainers to non-employee directors, and granted 238,500 stock options under the 2013 Equity Incentive Plan to non-employee directors. These option awards vest in equal annual installments over 3 years from the date of grant with a 10 year term, subject to continuing service requirements (see Note 6). Subsequently in February and March 2014, the Company’s Board of Directors approved grants of 97,298 stock options to employees and a non-employee director of the company, of which 54,298 stock options were granted as a result of the closing of the IPO pursuant to the terms of underlying employment agreements. Included in the stock options granted pursuant to the terms of underlying employment agreements are 53,108 option awards granted to the Company’s non-executive Chairman, which vested fully on the date of grant (see Note 6).
	Under the terms of certain employment agreements with executive officers, the Company incurred additional cash compensation expense of $150,000 immediately, and $225,000 annually, upon the closing of its IPO. All payments required under these agreements as a result of the closing of the Company’s IPO on February 10, 2014 have been subsequently made in February and March 2014, using the net proceeds from the IPO.
	During the quarter ended March 31, 2014, the Company repaid in full the remaining amounts outstanding of approximately $70,000 due for laboratory equipment under financing agreements with a supplier, which is a business owned by a member of the Company’s board of directors, using the net proceeds from the IPO.

Liquidity

Liquidity	3 Months Ended
Liquidity	Mar. 31, 2014
Text Block [Abstract]	'
Liquidity	'
	3. Liquidity
	At December 31, 2013 and March 31, 2014, the Company had accumulated deficits of approximately $122,421,000 and $127,549,000, respectively. For the quarters ended March 31, 2013 and 2014, the Company incurred net losses of approximately $1,926,000 and $5,128,000, respectively. While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses in the foreseeable future.
	Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the issuance of debt, and revenues from clinical laboratory testing through contracted partners. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant net revenues to achieve and sustain income from operations.
	As of March 31, 2014, cash and cash equivalents totaled approximately $10,417,000. On February 10, 2014, the Company received cash proceeds of approximately $17,390,000 as a result of the closing of its IPO, net of underwriting discounts and additional underwriting costs incurred (see Note 2). On April 30, 2014, the Company received net cash proceeds of approximately $4,927,000 pursuant to the execution of a term loan agreement with Oxford Finance LLC (see Note 9). Management believes that its cash resources should be sufficient to support currently forecasted operations through at least the next twelve months. However, the Company operates in a market that makes its prospects difficult to evaluate, and the possibility exists that the Company will need additional debt or equity financing in the future to execute on its current or future business strategies beyond the next twelve months. Management can provide no assurances that any sources of a sufficient amount of financing will be available to the Company on favorable terms, if at all.

Fair_Value_Measurement

Fair Value Measurement	3 Months Ended
Fair Value Measurement	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurement	'
	4. Fair Value Measurement
	The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their estimated fair values due to the short-term maturities of these financial instruments.
	Warrant Liability Derivatives
	The Company classified the fair value measurements of the Company’s warrant liability derivatives as Level 3 in all periods presented. The Company adjusted the carrying value of the warrants classified as liabilities until the completion of its IPO on February 10, 2014, at which time the exercise price was fixed at $10.00 per share and the fair value of the warrants was reclassified to shareholders’ deficit, except for a warrant for 1,587 preferred shares that remains outstanding at March 31, 2014 (see Note 2).
	The aggregate fair value of the Company’s warrant liability at the closing of the IPO on February 10, 2014 was estimated using a Black-Scholes valuation model with the following assumptions for the five-year term and two-year term common stock warrants, respectively:


		Five-year term			Two-year term
	Stock price	$	8.91		$	8.91
	Exercise price	$	10		$	10
	Expected dividend yield		0	%		0	%
	Discount rate-bond equivalent yield		1.48	%		0.32	%
	Expected life (in years)		5			2
	Expected volatility		90	%		90	%
	The fair value attributed to such warrants as of December 31, 2013 and March 31, 2014 is as follows:


		Fair Value Measurements Using
		Quoted Prices			Significant			Significant
		in Active			Other			Unobservable
		Markets for			Observable			Inputs
		Identical Assets			Inputs			(Level 3)
		(Level 1)			(Level 2)
	Liabilities
	Warrant Liability at December 31, 2013		—			—		$	2,140,532
	Warrant Liability at March 31, 2014		—			—		$	6,538
	The following table includes a summary of changes in the fair value of the warrants for the quarter ended March 31, 2014:


		Fair Value Measurements
		at Reporting Date Using
		Significant Unobservable
		Inputs (Level 3)
	Balance at December 31, 2013	$	2,140,532
	Warrant liability incurred in 2014		135,222
	Change in fair value in 2014		206,404
	Warrant liability reclassified to additional paid-in capital in 2014		(2,475,620	)

	Balance at March 31, 2014	$	6,538

	The change in the estimated fair value of the total warrant liability of approximately $318,000 and $(206,000) was recognized as a non-cash gain/(loss) and included in total other income/(expense) in the Company’s unaudited condensed statement of operations and comprehensive loss for the quarters ended March 31, 2013 and 2014, respectively.

	Other Fair Value Measurements
	In connection with the closing of the Company’s IPO on February 10, 2014, the IPO’s underwriters were granted a 45 day option to purchase up to 285,000 shares of common stock to cover overallotments with a grant date fair value of $202,143, which was not exercised. Additionally, certain designees of the representative of the underwriters were issued warrants to buy (in the aggregate) up to 95,000 shares of common stock with a grant date fair value of $544,116. The fair values of these stock option and common stock warrants were estimated using probability weighted Black-Scholes valuation models with the following assumptions:


		Options			Warrants
	Stock price	$	8.91		$	8.91
	Exercise price	$	9.3		$	12.5
	Expected dividend yield		0	%		0	%
	Discount rate-bond equivalent yield		0.07	%		1.46	%
	Expected life (in years)		0.12			5
	Expected volatility		70	%		90	%
	The estimated grant date fair values of these non-cash equity classified instruments are recorded as an offset to additional paid-in capital within common stock issuance costs in the Company’s unaudited condensed balance sheet at March 31, 2014.

Balance_Sheet_Details

Balance Sheet Details	3 Months Ended
Balance Sheet Details	Mar. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Balance Sheet Details	'
	5. Balance Sheet Details
	The following provides certain balance sheet details:


		December 31,		March 31,
		2013		2014
	Accrued Liabilities
	Accrued interest	$	524,885	$	—
	Accrued payroll		125,299		77,727
	Deferred wages		1,377,987		167,533
	Accrued vacation		213,601		235,086
	Other		286		213

	Total accrued liabilities	$	2,242,058	$	480,559

	As of December 31, 2013, the Company incurred $538,318 in costs directly associated with its IPO, which are reflected on the balance sheet as a component of prepaid expenses and other current assets. As of March 31, 2014, a balance of $1,211,896 of such costs, in addition to underwriting discounts of $1,330,000 and an aggregate $746,259 of associated stock option and restricted stock awards, are offset against additional paid-in capital as a result of the closing of the IPO on February 10, 2014 (see Note 2).

Stockbased_Compensation

Stock-based Compensation	3 Months Ended
Stock-based Compensation	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-based Compensation	'
	6. Stock-based Compensation
	A summary of stock option activity for option awards granted under the Company’s 2007 Equity Incentive Plan and 2013 Equity Incentive Plan for the quarter ended March 31, 2014 is as follows:


			Number of				Weighted				Average
			Shares				Average Exercise				Remaining
							Price Per Share				Contractual
											Term in Years
	Vested and unvested expected to vest, December 31, 2013			331,540			$	5.14				9.3

	Outstanding at December 31, 2013			333,106			$	5.14				9.3

	Granted			335,798			$	8.74
	Exercised			—				—
	Cancelled/forfeited/expired			(2,691	)			5.17

	Outstanding at March 31, 2014			666,213			$	6.96				9.4

	Vested and unvested expected to vest, March 31, 2014			664,254			$	6.96				9.4


	The intrinsic value of options outstanding at December 31, 2013 and March 31, 2014 was $8,204 and $726,735, respectively. The intrinsic value of options vested and unvested expected to vest at December 31, 2013 and March 31, 2014 was $8,192 and $722,479, respectively.
	The fair values of option awards granted during the quarter ended March 31, 2014 were estimated using a Black-Scholes pricing model with the following assumptions:


	Stock and exercise prices		$ 7.50 – $ 9.11
	Expected dividend yield		0.00%
	Discount rate-bond equivalent yield		1.56% – 1.98%
	Expected life (in years)		5.00 – 6.02
	Expected volatility		90.0% – 100.0%
	Expected forfeiture rate		0.00%
	Using the assumptions described above, with stock and exercise prices being equal on date of grant, the weighted-average estimated fair value of options granted in the quarter ended March 31, 2014 was approximately $6.78 per share.
	Further information about the options outstanding and exercisable at December 31, 2013 and March 31, 2014 is as follows:


	Options Outstanding and Exercisable at December 31, 2013
	Weighted Average Exercise Price				Total Shares				Weighted				Total Shares
					Outstanding				Average				Exercisable
									Contractual
									Life (in years)
		$4.62				20,208				7.3				13,731
		$5.04				12,460				5.5				12,455
		$5.18				300,438				9.6				110,825

						333,106								137,011



	Options Outstanding and Exercisable at March 31, 2014
	Weighted Average Exercise Price				Total Shares				Weighted				Total Shares
					Outstanding				Average				Exercisable
									Contractual
									Life (in years)
		$4.62				20,208				7				14,994
		$5.04				12,298				3.7				12,100
		$5.18				297,909				9.2				129,453
		$7.50				43,000				10				—
		$8.88				238,500				9.9				—
		$9.11				54,298				9.9				53,133

						666,213								209,680

	The intrinsic value of options exercisable at December 31, 2013 and March 31, 2014 was $5,575 and $348,232, respectively.
The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statement of operations and comprehensive loss during the periods presented:


		For the quarter ended
		March 31,
		2013				2014
Stock Options
Research and development expenses		$	3,758			$	70,034
General and administrative expenses			6,752				464,484
Sales and marketing expenses			—				1,214

Total expenses related to stock options			10,510				535,732

Restricted Stock Units (“RSUs”)
Research and development expenses			—				7,500
General and administrative expenses			—				351,708

Total stock-based compensation		$	10,510			$	894,940


As of March 31, 2014, total unrecognized stock-based compensation expense related to unvested stock option and RSU awards, adjusted for estimated forfeitures, was approximately $2,630,000 and $113,000, respectively, and is expected to be recognized over a weighted-average period of approximately 2.9 years and 1.3 years, respectively.

Net_Loss_per_Common_Share

Net Loss per Common Share	3 Months Ended
Net Loss per Common Share	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Net Loss per Common Share	'
	7. Net Loss per Common Share
	Basic and diluted net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the quarters ended March 31, 2013 and 2014, the outstanding shares of Series A preferred stock, RSUs, convertible debt, warrants, and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same.
	In November 2013, the Company effected a 1:14 reverse stock split of all common shares outstanding. The calculation of weighted-average shares outstanding has been adjusted for this reverse split as if it had occurred on January 1, 2013.
	The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:


		For the quarters ended March 31,
		2013		2014
	Series A preferred (number of common stock equivalents)		647,007		—
	Preferred warrants outstanding (number of common stock equivalents)		192,262		1,587
	Notes payable convertible into preferred shares (number of common stock equivalents)		614,077		—
	Preferred share RSUs (number of common stock equivalents)		33,158		73,151
	Common warrants outstanding		—		556,221
	Notes payable convertible into common shares		467,011		—
	Common share RSUs		54,615		133,971
	Common options outstanding		59,011		666,213

	Total anti-dilutive common share equivalents		2,067,141		1,431,143

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	8. Commitments and Contingencies
	In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings which are expected to have a material adverse effect on its financial condition, results of operations or liquidity.
	The Company’s former Vice President of Operations filed an administrative proceeding against the Company with the California Labor Commissioner in April 2013, seeking damages for alleged unpaid wages and penalties. A hearing was held on August 19, 2013 which resulted in a finding against the Company for approximately $65,000, of which $40,000 was paid during the year ended December 31, 2013 and $25,000 was accrued as of December 31, 2013. On February 25, 2014, the aforementioned administrative proceeding filed with the California Labor Commissioner by the Company’s former Vice President of Operations was settled in full following payment of the remaining $25,000 due.

Subsequent_Events

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	9. Subsequent Events
	Effective as of April 30, 2014, the Company entered into a loan and security agreement (the “Credit Facility”) in an aggregate principal amount of up to $10.0 million with Oxford Finance LLC (“Oxford”) for working capital and general business purposes. The first term loan under the Credit Facility was funded on April 30, 2014 in a principal amount of $5.0 million. A second term loan of up to a principal amount of $5.0 million will be funded at the Company’s request prior to December 31, 2015, subject to the achievement of product and services revenues of at least $9.0 million for the trailing six month period by November 30, 2015. In connection with the first term loan under the Credit Facility, a facility fee of $50,000 was charged and an additional $50,000 facility fee will be due upon execution of the second term loan under the Credit Facility. The Credit Facility is secured by substantially all of the Company’s assets other than its intellectual property. Each term loan under the credit facility bears interest at an annual rate equal to the greater of (i) 7.95% or (ii) the sum of (a) the three-month U.S. LIBOR rate reported in the Wall Street Journal three business days prior to the funding date of the applicable term loan, plus (b) 7.71%. The Company is required to make interest-only payments on the first term loan through February 1, 2016 if the funding date of the second term loan occurs before June 30, 2015, or through August 1, 2015 otherwise. If executed, interest-only payments are required to be made on the second term loan through February 1, 2016 if the funding date of the second term loan occurs before June 30, 2015, or through the seventh month following the funding date of the second term loan otherwise. The first term loan under the credit facility matures on July 1, 2018, and the second term loan matures on the first day of the 29th month following the end of the applicable interest-only period. Upon repayment of each term loan, the Company is also required to make a final payment equal to 5.50% of the original principal amount(s) funded. At the Company’s option, the outstanding principal balance of the term loans may be repaid in whole but not in part, subject to a prepayment fee of 3% of any amount prepaid if the prepayment occurs on or prior to April 30, 2015, 2% of the amount prepaid if the prepayment occurs after April 30, 2015 but on or prior to April 30, 2016, and 1% of any amount prepaid after April 30, 2016. Additionally, a warrant to purchase up to 52,966 shares of the Company’s common stock at an exercise price of $4.72 per share with a term of 10 years was issued to Oxford on April 30, 2014. Additional warrants for shares of the Company’s common stock will be issued upon execution of the second term loan under the Credit Facility in an amount equal to 5.0% of the funded amount divided by the exercise price, which will be equal to the lower of (i) the closing price per share of the Company’s common stock on the NASDAQ on the date prior to the funding date of the second term loan or (ii) the ten-day average closing price per share prior to the funding date of the second term loan. Issuance costs associated with the initial Term Loan borrowing on April 30, 2014 consisting of the common stock warrants and other costs deducted from the gross proceeds by the lender are recorded as a discount to outstanding debt and are amortized to interest expense utilizing the effective interest rate method.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	3 Months Ended
Basis of Presentation (Policies)	Mar. 31, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America.
	The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission (“SEC”) instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles (“GAAP”) to be included in a full set of financial statements. The unaudited condensed balance sheet at December 31, 2013 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2013, filed with the SEC with our Annual Report on Form 10-K on March 28, 2014 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.
The Company and Business Activities	'
	The Company and Business Activities
	Biocept, Inc. (“the Company”) was founded in California in May 1997 and is a commercial-stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) tests utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor.
	The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures CEE microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic tests in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The tests the Company offers are classified as laboratory developed tests (LDTs), under the CLIA regulations.
	In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In July 2013, the FASB issued authoritative guidance which requires netting unrecognized tax benefits against deferred tax assets for a loss or other carryforward that would apply in settlement of uncertain tax positions. This guidance is effective for annual reporting periods beginning after December 15, 2013, and was effective for the Company’s fiscal year beginning January 1, 2014. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures.

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	3 Months Ended
Fair Value Measurement (Tables)	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value of Warrant Liability	'
	The aggregate fair value of the Company’s warrant liability at the closing of the IPO on February 10, 2014 was estimated using a Black-Scholes valuation model with the following assumptions for the five-year term and two-year term common stock warrants, respectively:


		Five-year term			Two-year term
	Stock price	$	8.91		$	8.91
	Exercise price	$	10		$	10
	Expected dividend yield		0	%		0	%
	Discount rate-bond equivalent yield		1.48	%		0.32	%
	Expected life (in years)		5			2
	Expected volatility		90	%		90	%
Schedule of Fair Value of Warrants	'
	The fair value attributed to such warrants as of December 31, 2013 and March 31, 2014 is as follows:


		Fair Value Measurements Using
		Quoted Prices			Significant			Significant
		in Active			Other			Unobservable
		Markets for			Observable			Inputs
		Identical Assets			Inputs			(Level 3)
		(Level 1)			(Level 2)
	Liabilities
	Warrant Liability at December 31, 2013		—			—		$	2,140,532
	Warrant Liability at March 31, 2014		—			—		$	6,538
Summary of Changes in Fair Value of Warrants	'
	The following table includes a summary of changes in the fair value of the warrants for the quarter ended March 31, 2014:


		Fair Value Measurements
		at Reporting Date Using
		Significant Unobservable
		Inputs (Level 3)
	Balance at December 31, 2013	$	2,140,532
	Warrant liability incurred in 2014		135,222
	Change in fair value in 2014		206,404
	Warrant liability reclassified to additional paid-in capital in 2014		(2,475,620	)

	Balance at March 31, 2014	$	6,538

Assumptions Used for Determining Fair Values of Stock Option and Common Stock Warrants	'

	The fair values of these stock option and common stock warrants were estimated using probability weighted Black-Scholes valuation models with the following assumptions:



		Options			Warrants
	Stock price	$	8.91		$	8.91
	Exercise price	$	9.3		$	12.5
	Expected dividend yield		0	%		0	%
	Discount rate-bond equivalent yield		0.07	%		1.46	%
	Expected life (in years)		0.12			5
	Expected volatility		70	%		90	%

Balance_Sheet_Details_Tables

Balance Sheet Details (Tables)	3 Months Ended
Balance Sheet Details (Tables)	Mar. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Schedule of Accrued Liabilities	'
	The following provides certain balance sheet details:


		December 31,		March 31,
		2013		2014
	Accrued Liabilities
	Accrued interest	$	524,885	$	—
	Accrued payroll		125,299		77,727
	Deferred wages		1,377,987		167,533
	Accrued vacation		213,601		235,086
	Other		286		213

	Total accrued liabilities	$	2,242,058	$	480,559

Stockbased_Compensation_Tables

Stock-based Compensation (Tables)	3 Months Ended
Stock-based Compensation (Tables)	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Summary of Stock Option Activity for Option Awards Granted	'
	A summary of stock option activity for option awards granted under the Company’s 2007 Equity Incentive Plan and 2013 Equity Incentive Plan for the quarter ended March 31, 2014 is as follows:


			Number of				Weighted				Average
			Shares				Average Exercise				Remaining
							Price Per Share				Contractual
											Term in Years
	Vested and unvested expected to vest, December 31, 2013			331,540			$	5.14				9.3

	Outstanding at December 31, 2013			333,106			$	5.14				9.3

	Granted			335,798			$	8.74
	Exercised			—				—
	Cancelled/forfeited/expired			(2,691	)			5.17

	Outstanding at March 31, 2014			666,213			$	6.96				9.4

	Vested and unvested expected to vest, March 31, 2014			664,254			$	6.96				9.4


Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model	'
	The fair values of option awards granted during the quarter ended March 31, 2014 were estimated using a Black-Scholes pricing model with the following assumptions:


	Stock and exercise prices		$ 7.50 – $ 9.11
	Expected dividend yield		0.00%
	Discount rate-bond equivalent yield		1.56% – 1.98%
	Expected life (in years)		5.00 – 6.02
	Expected volatility		90.0% – 100.0%
	Expected forfeiture rate		0.00%
Schedule of Information about Options Outstanding and Exercisable	'
	Further information about the options outstanding and exercisable at December 31, 2013 and March 31, 2014 is as follows:


	Options Outstanding and Exercisable at December 31, 2013
	Weighted Average Exercise Price				Total Shares				Weighted				Total Shares
					Outstanding				Average				Exercisable
									Contractual
									Life (in years)
		$4.62				20,208				7.3				13,731
		$5.04				12,460				5.5				12,455
		$5.18				300,438				9.6				110,825

						333,106								137,011



	Options Outstanding and Exercisable at March 31, 2014
	Weighted Average Exercise Price				Total Shares				Weighted				Total Shares
					Outstanding				Average				Exercisable
									Contractual
									Life (in years)
		$4.62				20,208				7				14,994
		$5.04				12,298				3.7				12,100
		$5.18				297,909				9.2				129,453
		$7.50				43,000				10				—
		$8.88				238,500				9.9				—
		$9.11				54,298				9.9				53,133

						666,213								209,680

Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss	'
	The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statement of operations and comprehensive loss during the periods presented:


			For the quarter ended
			March 31,
			2013				2014
	Stock Options
	Research and development expenses		$	3,758			$	70,034
	General and administrative expenses			6,752				464,484
	Sales and marketing expenses			—				1,214

	Total expenses related to stock options			10,510				535,732

	Restricted Stock Units (“RSUs”)
	Research and development expenses			—				7,500
	General and administrative expenses			—				351,708

	Total stock-based compensation		$	10,510			$	894,940

Net_Loss_per_Common_Share_Tabl

Net Loss per Common Share (Tables)	3 Months Ended
Net Loss per Common Share (Tables)	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares	'
	The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:


		For the quarters ended March 31,
		2013		2014
	Series A preferred (number of common stock equivalents)		647,007		—
	Preferred warrants outstanding (number of common stock equivalents)		192,262		1,587
	Notes payable convertible into preferred shares (number of common stock equivalents)		614,077		—
	Preferred share RSUs (number of common stock equivalents)		33,158		73,151
	Common warrants outstanding		—		556,221
	Notes payable convertible into common shares		467,011		—
	Common share RSUs		54,615		133,971
	Common options outstanding		59,011		666,213

	Total anti-dilutive common share equivalents		2,067,141		1,431,143

Initial_Public_Offering_Additi

Initial Public Offering - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

Feb. 10, 2014

Feb. 04, 2014

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Feb. 13, 2014

Feb. 10, 2014

Mar. 31, 2014

Feb. 13, 2014

Mar. 31, 2014

Feb. 10, 2014

Mar. 31, 2014

Feb. 10, 2014

Mar. 31, 2014

Feb. 10, 2014

Mar. 31, 2014

Executive Officer [Member]

Employee [Member]

2013 Equity Incentive Plan [Member]

2008 Convertible Note [Member]

2013 Convertible Bridge Notes [Member]

Line of Credit [Member]

Convertible Bridge Notes and Line of Credit [Member]

Aegis Capital Corp. [Member]

Non-Employee Directors [Member]

Employees and a Non-Employee Director [Member]

Non Executive Chairman [Member]

Class of Stock [Line Items]

Initial public offering, number of shares issued

1,900,000

Initial public offering, price per share

$10

Net cash proceeds from issue of initial public offering after deducting underwriting discounts and additional costs

$17,390,000

$17,390,240

Increase in capital shares value

16,458,000

Additional costs incurred prior to, and associated with IPO, beginning of period

932,136

Purchase of common stock by underwriters to cover overallotments, number of shares

285,000

Purchase of common stock by underwriters to cover overallotments, per share

$9.30

Issuance of warrants to purchase shares of common stock

95,000

Exercise price of warrants

12.5

Overallotment issued to underwriter to purchase common stock, period

'45 days

Purchase of common stock by underwriters to cover overallotments, grant date fair value

202,143

Warrants to purchase common stock, period

'5 years

Issuance of warrants to purchase shares of common stock, grant date fair value

544,116

Series A Preferred Stock, shares converted to common stock

69,421,047

Common stock, shares issued upon conversion of Series A Preferred Stock

1,652,851

Common stock, shares authorized

40,000,000

53,000,000

Preferred stock, shares authorized

5,000,000

100,000,000

Convertible Note, principal amount

1,400,000

5,165,000

Convertible Note, accrued interest

233,982

313,017

Conversion price of notes

$10

Convertible Note converted into common stock

163,399

547,794

Warrants reclassified to additional paid-in capital

387,152

258,249

128,903

387,152

Collateral amount provided to secure Line of Credit

2,578,104

Shares of common stock vested as settlement of certain restricted stock units

73,151

Lock-up period

'180 days

Increase in number of shares of common stock covered by plan

800,000

Preferred warrants outstanding after cancellation of warrants due to early termination clauses

1,587

Derivative warrant liabilities

2,475,620

Unamortized discounts related to warrants

996,024

Non-cash underwriter IPO costs

279,760

Non-cash underwriter IPO discounts

1,330,000

Offering costs associated with IPO

932,136

Maximum amount of Line of Credit

2,600,000

Line of credit, outstanding balance repaid

2,346,000

Line of credit, accrued interest paid

27,043

152,507

1,765

Payment of deferred salary obligations

1,009,552

344,883

Stock options granted

335,798

54,298

238,500

97,298

53,108

Option awards vesting period

'3 years

Option awards expiration period

'10 years

Additional cash compensation expense

150,000

Annual cash compensation expense

225,000

Repayment of laboratory equipment dues to supplier

$70,000

Liquidity_Additional_Informati

Liquidity - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended				1 Months Ended
	Feb. 10, 2014	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Apr. 30, 2014
						Oxford Finance LLC [Member]
						Subsequent Events [Member]
Cash and Cash Equivalents [Line Items]	'	'	'	'	'	'
Accumulated deficit	'	($127,548,847)	'	($122,420,976)	'	'
Net loss	'	-5,127,871	-1,925,974	'	'	'
Cash and cash equivalents	'	10,417,277	17,964	69,178	185,256	'
Cash proceeds from IPO, net of underwriting discounts and additional costs	17,390,000	17,390,240	0	'	'	'
Net cash proceeds on term loan	'	'	'	'	'	$4,927,000

Fair_Value_Measurement_Additio

Fair Value Measurement - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Feb. 10, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Exercise price of warrants	10	'	10
Warrant for preferred shares outstanding	1,587	'	'
Change in estimated fair value of total warrant liability	$206,404	($317,993)	'
Overallotment issued to underwriter to purchase common stock, period	'45 days	'	'
Purchase of common stock by underwriters to cover overallotments, grant date fair value	202,143	'	'
Purchase of common stock by underwriters to cover overallotments, number of shares	285,000	'	'
Issuance of warrants to purchase shares of common stock, grant date fair value	$544,116	'	'
Aegis Capital Corp. [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Exercise price of warrants	12.5	'	'
Issuance of warrants to purchase shares of common stock	95,000	'	'

Fair_Value_Measurement_Schedul

Fair Value Measurement - Schedule of Fair Value of Warrant Liability (Detail) (USD $)	Feb. 04, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014
		Warrants [Member]	Five-Year Term [Member]	Two-Year Term [Member]
			Warrants [Member]	Warrants [Member]
Warrant Fair Value Black Scholes Method [Line Items]	'	'	'	'
Stock price	$10	$8.91	$8.91	$8.91
Exercise price	'	$12.50	$10	$10
Expected dividend yield	'	0.00%	0.00%	0.00%
Discount rate-bond equivalent yield	'	1.46%	1.48%	0.32%
Expected life (in years)	'	'5 years	'5 years	'2 years
Expected volatility	'	90.00%	90.00%	90.00%

Fair_Value_Measurement_Schedul1

Fair Value Measurement - Schedule of Fair Value of Warrants (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	$6,538	$2,140,532
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	0	0
Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	0	0
Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	$6,538	$2,140,532

Fair_Value_Measurement_Summary

Fair Value Measurement - Summary of Changes in Fair Value of Warrants (Detail) (Warrants [Member], USD $)	3 Months Ended
	Mar. 31, 2014
Warrants [Member]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Beginning Balance	$2,140,532
Warrant liability incurred in 2014	135,222
Change in fair value in 2014	206,404
Warrant liability reclassified to additional paid-in capital in 2014	-2,475,620
Ending Balance	$6,538

Fair_Value_Measurement_Assumpt

Fair Value Measurement - Assumptions Used for Determining Fair Values of Stock Option and Common Stock Warrants (Detail) (USD $)	Feb. 04, 2014	Mar. 31, 2014	Mar. 31, 2014
	Feb. 04, 2014	Options [Member]	Warrants [Member]
Warrant Fair Value Black Scholes Method [Line Items]	'	'	'
Stock price	$10	$8.91	$8.91
Exercise price	'	$9.30	$12.50
Expected dividend yield	'	0.00%	0.00%
Discount rate-bond equivalent yield	'	0.07%	1.46%
Expected life (in years)	'	'1 month 13 days	'5 years
Expected volatility	'	70.00%	90.00%

Balance_Sheet_Details_Schedule

Balance Sheet Details - Schedule of Accrued Liabilities (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Accrued Liabilities	'	'
Accrued interest	$0	$524,885
Accrued payroll	77,727	125,299
Deferred wages	167,533	1,377,987
Accrued vacation	235,086	213,601
Other	213	286
Total accrued liabilities	$480,559	$2,242,058

Balance_Sheet_Details_Addition

Balance Sheet Details - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Cost related to IPO Issuance [Abstract]	'	'
Cost related to IPO issuance	$932,136	$538,318
Additional stock issuance cost offset against paid-in capital	1,211,896	'
Underwriting discounts offset against paid-in capital	1,330,000	'
Stock option and restricted stock offset against paid-in capital	$746,259	'

Stockbased_Compensation_Summar

Stock-based Compensation - Summary of Stock Option Activity for Option Awards Granted (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Number of Shares, Vested and unvested expected to vest, Beginning Balance	331,540	'
Number of Shares Outstanding, Beginning Balance	333,106	'
Number of Shares, Granted	335,798	'
Number of Shares, Exercised	0	'
Number of Shares, Cancelled/forfeited/expired	-2,691	'
Number of Shares Outstanding, Ending Balance	666,213	333,106
Number of Shares, Vested and unvested expected to vest, Ending Balance	664,254	331,540
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Beginning Balance	$5.14	'
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	$5.14	'
Weighted Average Exercise Price Per Share, Granted	$8.74	'
Weighted Average Exercise Price Per Share, Exercised	$0	'
Weighted Average Exercise Price Per Share, Cancelled/forfeited/expired	$5.17	'
Weighted Average Exercise Price Per Share, Outstanding Ending balance	$6.96	$5.14
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Ending Balance	$6.96	$5.14
Average Remaining Contractual Term in Years, Outstanding	'9 years 4 months 24 days	'9 years 3 months 18 days
Average Remaining Contractual Term in Years, Vested and unvested expected to vest	'9 years 4 months 24 days	'9 years 3 months 18 days

Stockbased_Compensation_Additi

Stock-based Compensation - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Intrinsic value of options outstanding	$726,735	$8,204
Intrinsic value of options vested and unvested expected to vest	722,479	8,192
Option awards assumptions, method used	'Black-Scholes pricing model	'
Weighted-average estimated fair value of options granted	$6.78	'
Intrinsic value of options exercisable	348,232	5,575
Unrecognized stock-based compensation expense, stock options	2,630,000	'
Unrecognized stock-based compensation expense, RSU awards	$113,000	'
Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Unrecognized stock-based compensation expense, weighted-average recognition period	'2 years 10 months 24 days	'
Restricted Stock Units ("RSUs") [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Unrecognized stock-based compensation expense, weighted-average recognition period	'1 year 3 months 18 days	'

Stockbased_Compensation_Assump

Stock-based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Expected dividend yield	0.00%
Expected volatility, minimum	90.00%
Expected volatility, maximum	100.00%
Expected forfeiture rate	0.00%
Minimum [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Stock and exercise prices	7.5
Discount rate-bond equivalent yield	1.56%
Expected life (in years)	'5 years
Maximum [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Stock and exercise prices	9.11
Discount rate-bond equivalent yield	1.98%
Expected life (in years)	'6 years 7 days

Stockbased_Compensation_Schedu

Stock-based Compensation - Schedule of Information about Options Outstanding and Exercisable (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Total Shares Outstanding	666,213	333,106
Total Shares Exercisable	209,680	137,011
Weighted Average Exercise Price 4.62 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted Average Exercise Price	$4.62	$4.62
Total Shares Outstanding	20,208	20,208
Weighted Average Contractual Life (in years)	'7 years	'7 years 3 months 18 days
Total Shares Exercisable	14,994	13,731
Weighted Average Exercise Price 5.04 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted Average Exercise Price	$5.04	$5.04
Total Shares Outstanding	12,298	12,460
Weighted Average Contractual Life (in years)	'3 years 8 months 12 days	'5 years 6 months
Total Shares Exercisable	12,100	12,455
Weighted Average Exercise Price 5.18 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted Average Exercise Price	$5.18	$5.18
Total Shares Outstanding	297,909	300,438
Weighted Average Contractual Life (in years)	'9 years 2 months 12 days	'9 years 7 months 6 days
Total Shares Exercisable	129,453	110,825
Weighted Average Exercise Price 7.5 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted Average Exercise Price	$7.50	'
Total Shares Outstanding	43,000	'
Weighted Average Contractual Life (in years)	'10 years	'
Total Shares Exercisable	0	'
Weighted Average Exercise Price 8.88 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted Average Exercise Price	$8.88	'
Total Shares Outstanding	238,500	'
Weighted Average Contractual Life (in years)	'9 years 10 months 24 days	'
Total Shares Exercisable	0	'
Weighted Average Exercise Price 9.11 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted Average Exercise Price	$9.11	'
Total Shares Outstanding	54,298	'
Weighted Average Contractual Life (in years)	'9 years 10 months 24 days	'
Total Shares Exercisable	53,133	'

Stockbased_Compensation_Effect

Stock-based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Stock Options [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total stock-based compensation	$535,732	$10,510
Restricted Stock Units ("RSUs") [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total stock-based compensation	894,940	10,510
Research and Development Expenses [Member] \| Stock Options [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total stock-based compensation	70,034	3,758
Research and Development Expenses [Member] \| Restricted Stock Units ("RSUs") [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total stock-based compensation	7,500	0
General and Administrative Expenses [Member] \| Stock Options [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total stock-based compensation	464,484	6,752
General and Administrative Expenses [Member] \| Restricted Stock Units ("RSUs") [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total stock-based compensation	351,708	0
Selling and Marketing Expenses [Member] \| Stock Options [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total stock-based compensation	$1,214	$0

Net_Loss_per_Common_Share_Addi

Net Loss per Common Share - Additional Information (Detail)	1 Months Ended	3 Months Ended
Net Loss per Common Share - Additional Information (Detail)	Nov. 30, 2013	Mar. 31, 2014
Earnings Per Share [Abstract]	'	'
Reverse stock split of common shares outstanding, ratio	0.0714	'
Reverse stock split, description	'	'In November 2013, the Company effected a 114 reverse stock split of all common shares outstanding. The calculation of weighted-average shares outstanding has been adjusted for this reverse split as if it had occurred on January 1, 2013.

Net_Loss_per_Common_Share_Sche

Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive common share equivalents	1,431,143	2,067,141
Series A Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive common share equivalents	0	647,007
Preferred Warrants Outstanding [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive common share equivalents	1,587	192,262
Notes Payable Convertible into Preferred Shares [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive common share equivalents	0	614,077
Preferred Share RSUs [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive common share equivalents	73,151	33,158
Common Warrants Outstanding [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive common share equivalents	556,221	0
Notes Payable Convertible into Common Shares [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive common share equivalents	0	467,011
Common Share RSUs [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive common share equivalents	133,971	54,615
Common Options Outstanding [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive common share equivalents	666,213	59,011

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended
	Feb. 25, 2014	Dec. 31, 2013	Aug. 19, 2013
Commitments And Contingencies Disclosure [Abstract]	'	'	'
Alleged unpaid wages and penalties	'	'	$65,000
Alleged unpaid wages and penalties, paid	'	40,000	'
Alleged unpaid wages and penalties, accrued	'	25,000	'
Alleged unpaid wages and penalties, accruals paid	$25,000	'	'

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)

3 Months Ended

0 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Feb. 10, 2014

Apr. 30, 2014

Subsequent Events [Member]

First Term Loan [Member]

Second Term Loan [Member]

One Year [Member]

Two Years [Member]

Three Years [Member]

Oxford Finance LLC [Member]

Subsequent Events [Member]

Line of Credit [Member]

First Term Loan [Member]

Second Term Loan [Member]

Subsequent Events [Member]

Subsequent Event [Line Items]

Debt instrument initial principal amount

$10,000,000

$5,000,000

Revenues product and service

28,275

35,154

9,000,000

Credit Facility, additional facility fee due

$50,000

Credit Facility interest rate, description

'Each term loan under the credit facility bears interest at an annual rate equal to the greater of (i) 7.95% or (ii) the sum of (a) the three-month U.S. LIBOR rate reported in the Wall Street Journal three business days prior to the funding date of the applicable term loan, plus (b) 7.71%. The Company is required to make interest-only payments on the first term loan through February 1, 2016 if the funding date of the second term loan occurs before June 30, 2015, or through August 1, 2015 otherwise.

Debt instrument, LIBOR percentage

7.71%

Percentage of final interest payment due at maturity

5.50%

5.00%

Warrant issued to lender

52,966

Warrant term

'10 years

Warrant exercise price

4.72

Term Loan prepayment fee

3.00%

2.00%

1.00%